Shapiro, H. S. (1967), *Methods Enzymol. 12A*, 205.
Strauss, B., and Hill, T (1970), *Biochim. Biophys. Acta 213*, 14.
Strauss, B., and Robbins, M. (1968), *Biochim. Biophys. Acta 161*, 68.
Studier, F. W. (1965), *J. Mol. Biol. 11*, 373.
Studier, F. W. (1969), *J. Mol. Biol. 41*, 189.
Szybalski, W. (1968), Fractions (Spinco Division, Beckman Instruments), (1).
Tamm, C., Shapiro, H. S., Lipshitz, R., and Chargaff, E. (1953), *J. Biol. Chem. 203*, 673.
Thomas, C. A. (1956), *J. Amer. Chem. Soc. 78*, 1861.
Wolfrom, M. L., and Thompson, A. (1963), *Methods Carbohyd. Chem. 2*, 65.

CORRECTIONS

"IUPAC–IUB Revised Tentative Rules for Nomenclature of Steroids," Volume 8, Number 6, June 1969, page 2227. The following amendments have been made by IUPAC–IUB.

On page 2227: Under Contents, Rule 2S-10, for Hetero read Heterocyclic.

Add the following to the footnote: The commissions are greatly indebted to R. S. Cahn, formerly Titular Member and later Associate Member of the Commission on the Nomenclature of Organic Chemistry, who has taken a great part in the work on nomenclature of steroids.

Column 2, paragraph 3: delete the last sentence (Decisions on . . . dealing with them).

Page 2228: Under 1.1, delete "or order of complexity." For Rule* C-15.11(e), read Nomenclature of Organic Chemistry, Section C (Butterworths, London, 1971). Delete footnote.

Under 1.4, last line, delete "is unspecified."

Under 1.5, Notes, add: If two carbon chains are attached at position 17, see notes 4 and 5 [found in these addenda] to Rule 2S-2.3.

Page 2230: The name under formula 31 should be 19(10→9β)*abeo*-5α,10α-lanostane. Added to these formulas should be



31A
5α-Protostane
4,4,8,14-Tetramethyl-18-nor-5α,8α,9β,13α,14β,17β,20*R*-cholestane (this is an important biogenetic precursor of tetracyclic triterpenoids and steroids)

Under 2.3, Notes, should be added:

(4) If a steriod has two carbon chains attached at position 17 and one of them is included in Table I under Rule 2.3, the compound is named as a 17-alkyl derivative of the steroid in the table carrying that substituent [*e.g.*, 17-methyl-5α-pregnane (31B); 17-propyl-5α,17α-cholestane (31C)].

(5) If a steroid has two carbon chains attached at position 17, neither of which is included in Table I under Rule 2.3, the compound is named as a 17,17-disubstituted androstane [*e.g.*, 17,17-dimethyl-5α-androstane (31D); 17α-methyl-17β-propyl-5α-androstane (31E)].



31B 31C



31D 31E

Page 2232: Column 2, line 28, delete unspecified or. Formula A should be amended at C-24 and its name corrected.



A
Name of A should be (24*R*,25*R*)-24-Bromo-5β-spirostan-3β-ol

Page 2233: In formula 55, for (20*R*,22*R*,25*R*), read (20*R*,-25*R*). In 56 and 59, the ends of the side chains should be redrawn, as shown. This makes the epimerism with 57 and 58 clearer.



56, 59

Page 2234: Table II, formula 55, for (20*R*,22*R*,25*R*) read

(20*R*,25*R*). Column 2, lines 1 and 2 from bottom, for 3β,17α,-20α read 3β,17,20α.

Page 2235: In the names under formulas 60–63, for 17(αH) or 17(βH), read 17α(H) or 17β(H). To Rule 5.2, add the Note: The prefix *retro*, indicating 9β,10α configuration, is not recommended for systematic nomenclature.

Page 2237: Rule 7.1, lines 4 and 5, for italic letter read italic capital letter. In the footnote, replace the second clause by: they are placed after any prefixes denoting substituents and before any stereochemical prefixes required by Rule 2S-1.5, or if there are none of the latter, then immediately before the stem name.

Page 2238: In the footnote, for 5α,10(αH), read 5α,10α(H).

Page 2239: Rules 2S-9 and 2S-11, delete New.

The *abeo* names of compounds 95–98 are to be amended as follows: (95) 5(10→1)*abeo*-1α(H),5α-androstane; (96) 14-(13→12)*abeo*-5β,12β(H)-chol-13(17)-en-24-oic acid; (97) 14-(8→9)*abeo*-5α,9ξ-cholestane (this configuration at C-9, if known, is assigned by the sequence-rule procedure (for reference, see footnote on p 2227); (98) 1(10→6)*abeo*-5β,6β(H)-androstane (an anthrasteroid).

The names of these compounds, according to Rule 2S-7.4 ("homo–nor" system), are as follows: (95) 9aβ-methyl-*B* (*9a*)-homo-*A*-nor-5α,10α-estrane; (96) (4*R*)-4-(17a-methyl-*D*-homo-*C*-nor-18-nor-5β-androst-17-en-17-yl)pentanoic acid, or 17-[(1*R*)-3-carboxy-1-methylpropyl]-17a-methyl-*D*-homo-*C*-nor-18-nor-5β-androst-17-ene; 97 cannot conveniently be named by the "homo–nor" system; 98: the"homo–nor" system is not appropriate.

Page 2240: In formula 109, for C read CH_3 (C-19).

Page 2241: In column 2, lines 1 and 6, for 2′H read 3′H.

"A New Model for the Binding of Flexible Ligands to Proteins," by Nora Laiken and George Némethy, Volume 10, Number 11, May 25, 1971, page 2101.

On page 2104, in the legend to Figure 6, the explanation of experimental points should read as follows: Experimentally determined ΔF_1° values (as given in references listed in the text) are presented for the binding of carboxylic acids (solid vertical bars, ⌶) and alkyl sulfates (broken vertical bars, ⌶) to serum albumin. The lengths of the bars indicate the ranges of the reported experimental values.

"Solute Perturbation of Protein Fluorescence. The Quenching of the Tryptophyl Fluorescence of Model Compounds and Lysozyme by Iodide Ion," by Sherwin S. Lehrer, Volume 10, Number 17, August 17, 1971, page 3254.

On page 3262, column 2, line 36, the last sentence(s) should read "The dependence of the quenching with pH may also provide information regarding the proximity of ionizing groups to fluorophors through the sensitivity of k_3 to local charge for charged quenchers. Additional information regarding energy transfer (Teale and Badley, 1970) and denaturation mechanisms may possibly also be obtained by this technique."

"IUPAC Commission on the Nomenclature of Organic Chemistry (CNOC) and IUPAC–IUB Commission on Biochemical Nomenclature (CBN): Tentative Rules for Carbohydrate Nomenclature," Volume 10, Number 21, October 12, 1971, page 3983.

The page numbers under Contents are those of *European Journal of Biochemistry*, who provided the reproduction proofs, and not those of *Biochemistry*.

"Binding of Tryptamine and 5-Hydroxytryptamine (Serotonin) to Nucleic Acids. Fluorescence and Proton Magnetic Resonance Studies," by Claude Hélène, Jean-Luc Dimicoli, and Francine Brun, Volume 10, Number 20, September 28, 1971, page 3802.

Equation 9 should read

$$\frac{D}{[A]_0[B]_0} = K\epsilon_{AB}{}^{\lambda} l - K\frac{D}{[A]_0}$$

instead of

$$\frac{D^{\lambda}}{[A]_0[B]_0} = \frac{1}{\epsilon_{AB}{}^{\lambda} \times l} + \frac{1}{\epsilon_{AB}{}^{\lambda} \times l}\frac{1}{K}\frac{D}{[A]_0}$$

"Investigation of the Active Center of Trypsin Using Photochromic Substrates," by Mark A. Wainberg and Bernard F. Erlanger, Volume 10, Number 21, October 12, 1971, page 3816.

In Table I: k_{cat} for *trans*-PABH should be 1.3 sec^{-1} instead of 3.3 sec^{-1}.

On page 3817, in the paragraph beginning "Irradiation of the substrate" 100 μl of solution was added to 150 ml of 0.02 M KCl, not to 200 ml.

Under References, the names of Niemann and Vratsanos have been missspelled in one instance each.